Human leukocyte antigen (HLA)-G gene polymorphism in patients with non-small cell lung cancer

Aneta Kowal¹, Andrzej Wiśniewski², Piotr Kuśnierzcyk² & Renata Jankowska¹

¹ Department of Pulmonology and Lung Cancer, Wrocław Medical University, Wrocław, Poland
² Laboratory of Immunogenetics, Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland

Keywords
HLA-G; lung cancer; promoter; single nucleotide polymorphism.

Correspondence
Aneta Kowal, Department of Pulmonology and Lung Cancer, Wrocław Medical University, Ul. Grabiszynska 105, 53-439 Wrocław, Poland.
Tel: +48 71 33 49 559
Fax: +48 71 33 49 596
Email: aneta.kowal@umed.wroc.pl

Received: 27 September 2014; Accepted: 22 December 2014.
doi: 10.1111/1759-7714.12232
Thoracic Cancer 6 (2015) 613–619 © 2015 The Authors. Thoracic Cancer published by Tianjin Lung Cancer Institute and Wiley Publishing Asia Pty Ltd
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

Abstract

Background: Lung cancer represents the highest morbidity and mortality caused by neoplasms in the world; therefore researchers continue to search for new tools to diagnose and treat the disease. The aim of the study was to establish the role of single nucleotide polymorphisms (SNP) in the promoter region of the human leukocyte antigen (HLA)-G gene in patients with non-small cell lung cancer.

Methods: We enrolled 143 patients with a mean age of 63 years, diagnosed with non-small cell lung cancer, in the study. Adenocarcinomas made up 33% of the cases. Patients in stage III or IV of the tumor node metastasis staging system made up 59%.

Results: All genotyped SNPs were in Hardy-Weinberg equilibrium. No proof of a relationship between genotype −725C>G>T and −716T>G and the risk of lung cancer compared with healthy volunteers from the literature was found. We also found no correlation between the two SNPs and survival time, histological type of cancer, T stage, the presence of remote metastases or performance status according to the Eastern Cooperative Oncology Group (ECOG) scale. The only association we found was genotype −725C>G>T and the degree of lymph node metastases (N stage).

Conclusions: SNPs of the promoter of the HLA-G gene may have an impact on the development of lymph node metastases. In the study we did not prove a relationship between the examined SNPs and the course of the disease because of the small patient groups studied.

Introduction

According to available statistics, lung cancer is the most frequently recognized neoplasm in the world. Symptoms of the disease usually appear in the late stage, which results in poor prognosis.

There are two main types of lung cancer, which differ in clinical course and susceptibility to treatment and prognosis: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). NSCLC is more frequent and is subdivided into squamous cell carcinoma, adenocarcinoma, large cell carcinoma, and a few other less frequent subtypes. Diagnosis is based on cytological and histological examination of different specimen biopsies. Treatment of lung cancer consists of thoracic surgery procedures, chemotherapy, radiotherapy, and combinations of these methods. However, the efficacy of these therapies remains poor.

The aetiology of lung cancer is not yet fully known. According to the cancer immunoediting hypothesis, supervision of the immune system may be crucial to eliminate tumor cells until the escape phase. There are many mechanisms which take part in cancer immunosurveillance, but cancer cells also develop different mechanisms to escape from elimination or equilibrium phases. One of them may be a change in HLA (human leukocyte antigen) molecule expression on the cancer cell surface. The main role of HLA class I molecules is to present autoantigens to cytotoxic T lymphocytes, which protect the cells against lymphocyte activation and also against NK cell reaction. HLA-G belongs to the non-classical major histocompatibility complex class I molecules, which are expressed only in immunoprivileged tissues, such as the fetomaternal barrier. Because of its expression, the cytrophoblast is protected against maternal immunological immunocytotoxicity.
One of the mechanisms of the escape phase revealed by cancer cells is the loss of HLA molecules to become invisible for T lymphocytes. But this leads to an NK cell reaction. HLA-G expression on cancer cells is the mechanism of specific immune tolerance function that makes them resistant to cytotoxicity of NK cells and cytotoxic T lymphocytes.\textsuperscript{20,21} There is some evidence that HLA-G expression takes part in the pathology of different neoplasms, including lung cancer.\textsuperscript{22,23} Increased expression of HLA-G has been found in many different solid tumors.\textsuperscript{24,25}

The HLA-G gene polymorphism is very limited.\textsuperscript{26,27} Polymorphism of the promoter region may influence HLA-G levels caused by different affinity of transcriptional and post-transcriptional factors.\textsuperscript{28} To date, 29 SNPs in the promoter region of the HLA-G gene have been reported.\textsuperscript{29}

The aim of the study was to establish the role of HLA-G gene polymorphism in patients with NSCLC. We analysed two single nucleotide polymorphisms (SNPs) in the promoter region of the HLA-G gene, $-725C>G$ and $-716T>G$, which may have an influence on gene expression.

### Materials and methods

#### Patient data

One hundred and forty-three patients diagnosed with NSCLC were enrolled in the study. They were hospitalized in the Department of Pulmonology and Lung Cancer, Medical University of Wroclaw, in 2010–2012. Diagnosis was based on cytological or histological examination. Patients were divided into groups according to the World Health Organization classification of tumors (2004) and the tumor node metastasis (TNM) staging system (7th edition).\textsuperscript{30} Clinical characteristics of patients included the Eastern Cooperative Oncology Group scale and history of smoking.\textsuperscript{31} Blood samples were collected before any oncological therapies. Patients were treated with chemotherapy, radiotherapy or surgery according to recommendations. We observed the response to the treatment and the course of the disease. The treatment response was mainly based on radiological examinations including chest computed tomography (CT, Response Evaluation Criteria in Solid Tumors), chest X-rays, if chest CTs were not available, and clinical data, such as the appearance of remote metastases (central nervous system, bones, adrenal glands). Lymphangitis carcinomatosa, pleural effusion, infiltration of thorax tissues or metastases to the other lung resulted from progression of the disease.

#### Polymerase chain reaction genotyping

Genetic examinations were performed at the Laboratory of Immunogenetics, Ludwik Hirsfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences in Wroclaw. There were four stages of the molecular procedure: genomic DNA extraction from whole blood leukocytes (Invisorb Spin Blood Midi Kit, Protocol 2, Strateg Molecular, Stratec Biomedical AG, Birkenfeld, Germany); spectrophotometric measurement of concentrations and purity of DNA preparations; amplification of the fragments of the HLA-G gene promoter region containing analysed SNPs (polymerase chain reaction, PCR); and temperature gradient gel electrophoresis (TGGE).

#### Electrophoresis

Temperature gradient gel electrophoresis was used to obtain different band patterns of the HLA-G gene promoter fragment. This method enables diagnosis of SNPs within DNA fragments of the same length because the presence of SNP changes the denaturation temperature of the DNA strand in the gel.

We compared the results of our group of patients with results published by Wiśniowski et al.\textsuperscript{32} In their study, a group of healthy controls (288 volunteers) were diagnosed using the same method by the same researcher. The control cohort was ethnically matched (Polish caucasians) and consisted of 171 women and 117 men; the mean age (for 164 individuals, for whom this information was available) was 31.3 ± 9.8 years.

The Bioethics Committee of the Medical University of Wroclaw approved the study. Informed consent was obtained from the included patients.

#### Statistical analysis

The median was used as the location parameter. Additionally, first and third quartiles and minimal and maximal observations were reported. Time to death was analysed with the proportional hazards model and survivor function was estimated with the Kaplan-Meier curve. Departure from the Hardy-Weinberg equilibrium was tested with the Chi-
squared test. In the case of small numbers, distribution of the test statistics was estimated numerically. Odds ratio (OR) was computed as the measure of effect size. When it was reasonable, we assumed a log additive model of association between genotypes and clinical variables. Row effect, column effect, and row-column effect models were used to test associations in the two-way contingency tables. Analysis was performed with the R.2.14 platform (R Foundation for Statistical Computing, Vienna, Austria).

**Results**

Among 143 patients there were 33 women and 110 men of mean age 63 ± 6 years. The most frequently diagnosed histological type was adenocarcinoma (33%) (Table 1). Squamous cell carcinoma represented 30% of the diagnoses and large cell carcinoma 10%, but 27% remained not otherwise specified carcinomas. Thirty-one percent of the patients were in stage IV of the disease and 28% in stage III according to the four-stage system of cancer progression, based on TNM.

Seventy-five patients (52.4%) underwent surgery, with 53 of these patients subsequently treated with chemotherapy and/or radiotherapy. In 18 patients, only behavioral therapy was applied. Most of the patients treated with chemotherapy (41.5%) stabilized (the effect was observed during and at the end of chemotherapy), and 41.1% of operated patients had no relapse (during the time of observation). However, in 61 patients, the disease course was not known. During the observation period, 51 patients died, and the median survival time was six months.

At the genotype level: for rs1233334 (−725C>G>T) in Polish caucasians (N = 288), we found 70.5% C/C, 25.0% C/G, 1.1% G/G, 3.1% C/T, and 0.3% G/T. In the SNP data-base, we found 85.0% C/C and 15.0% C/G; other genotypes were not detected in caucasians (N = 60 only) by the method used. There was no information on the distribution of −716T>G (rs2249863) in caucasians in the database.

All genotyped SNPs were in Hardy-Weinberg equilibrium (Tables 2, 3), which means that analysed polymorphic sites were not under any disrupting factors, especially those of natural selection. On the other hand, new alleles are of low

### Table 2 Distribution of genotypes and allele frequencies of −725C>G>T of the HLA-G gene in patients with lung cancer

| Genotypes | CC | CG | CT | GG | GT | TT | Total |
|-----------|----|----|----|----|----|----|-------|
| n         | 97 | 34 | 7  | 2  | 3  | 0  | 143   |
| %         | 67.83 | 23.78 | 4.9 | 1.4 | 2.1 | 0  | 100%  |

| Alleles | C | G | T | Total |
|---------|---|---|---|-------|
| n       | 235 | 41 | 10 | 286   |
| %       | 82.17 | 14.34 | 3.5 | 100%  |

Hardy-Weinberg principle calculation

χ² = 3.237  
*P = 0.7528*

*P- Monte Carlo method. HLA, human leukocyte antigen.

### Table 3 Distribution of genotypes and allele frequencies of −716 T>G of the HLA-G gene in patients with lung cancer

| Genotypes | TT | GT | GG | Total |
|-----------|----|----|----|-------|
| n         | 43 | 70 | 30 | 143   |
| %         | 30.07 | 48.95 | 20.98 | 100%  |

| Alleles | T | G | Total |
|---------|---|---|-------|
| n       | 156 | 130 | 286   |
| %       | 54.55 | 45.45 | 100%  |

H-W

χ² = 0.023  
P = 0.8782

HLA, human leukocyte antigen.

### Table 4 Distribution of genotypes frequencies of −725C>G>T of the HLA-G gene in patients with lung cancer and controls

| Group | 0 C alleles in genotype | 1 GT or GG | 2 CT or CG | 3 CC | Total |
|-------|-------------------------|------------|------------|------|-------|
| Patients | n | 5 | 41 | 97 | 143   |
| % | 3.5 | 28.67 | 67.83 | 100%  |
| Control | n | 4 | 81 | 203 | 288   |
| % | 1.39 | 28.13 | 70.49 | 100%  |
| OR | 2.62 | 1.06 | 1† | – | – |
| CI 95% dla OR | 0.69; 9.96 | 0.68; 4.09 | – | – |

χ² = 0.83  
P = 0.3623

†Homozygotes CC as reference group. CI, confidence interval; HLA, human leukocyte antigen; OR, odds ratio.
frequencies, and even if natural selection acts against them, it is too difficult to detect within such a small patient sample. At the genotype level, the frequencies of the −725CC and −716GT genotypes were the highest. Neither the −725C > G > T nor the −103T > G genotype predisposes to lung cancer (P = 0.7528 and P = 0.2998, respectively).

No proof of a relationship between the genotype −725C > G > T and the risk of lung cancer compared with healthy volunteers from the literature was found (Tables 4, 5). The group of patients did not differ from the control group (P = 0.3623). Table 4 shows that heterozygotes with one C allele (CG or CT) at the −210 site have the same risk of developing the disease as homozygotes with CC alleles (OR = 1.06). Patients without C alleles (GT or GG) have twice as high a risk of becoming ill compared to CC patients (OR = 2.62), but we have no proof that the result is not a random sampling error (confidence interval [CI] 95% for OR 0.69; 9.96). We did not find a correlation between the two SNPs and survival time. We noted that patients with genotype CC at the −725 site had a 13% lower risk of death than CG and CT patients and 29% lower than GG and GT patients, but the result may be accidental (P = 0.6998). There was no evidence of any relationship between the SNPs and the histological type of cancer. There was also no impact of the examined genotypes on the T and M stages of the TNM scale. What we found was the correlation of genotype −725C > G > T and the extent of lymph node metastases: more C alleles in the genotype lead to a more advanced N stage (P = 0.0319) (Table 6). The risk that a patient with more C alleles than another patient also has more advanced lymph node metastases was 37% higher. There was no such correlation with genotype −716T > G. We also noted a tendency of a poorer response to chemotherapy in patients with more C alleles at the −725 position and patients with more T alleles at the −716 position (Tables 7, 8). Together with more C alleles at the −725 site, the frequency of partial regression decreases and increases the probability of stabilization and progression. If a patient with GT at the −716 site reacted with partial regression to chemo-

**Table 5** Distribution of genotypes frequencies of −716 T > G of HLA-G gene in patients with lung cancer and controls

| Group       | T alleles in genotype | 0 | 1 | 2 | Total |
|-------------|-----------------------|---|---|---|-------|
|             | GG                    | 30| 70| 43| 143   |
| Patients    | %                     | 20.98| 48.95| 30.07|       |
| Control     | %                     | 65 | 153| 70 | 288   |
| OR          |                       | 0.75 | 0.74 | 1† | –     |
| CI 95% dla OR |                     | 0.42; 1.34 | 0.46; 1.19 | – | –     |
| OR total    |                       | 0.83 | 0.495 (0.61; 1.11) |

†Homozygotes TT as reference group. CI, confidence interval; OR, odds ratio.

**Table 6** Lymph nodes metastases correlation with genotype −725C > G > T

| Lymph node metastases† | N0 | % | N1 | % | N2 | % | N3 | % | Total | % |
|------------------------|----|---|----|---|----|---|----|---|-------|---|
| −725C > G > T          |    |   |    |   |    |   |    |   |       |   |
| CC                     | 31 | 34.4 | 12 | 13.3 | 33 | 36.7 | 14 | 15.6 | 90 | 100% |
| CG                     | 20 | 58.8 | 5  | 14.7 | 5  | 14.7 | 4  | 11.8 | 34 | 100% |
| CT                     | 4  | 57.1 | 1  | 14.3 | 2  | 28.6 | 0  | 0    | 7  | 100% |
| GG                     | 0  | 0    | 1  | 50  | 0  | 0    | 1  | 50   | 2  | 100% |
| GT                     | 2  | 66.7 | 0  | 0   | 1  | 33.3 | 0  | 0    | 3  | 100% |
| Razem                  | 57 | 41.9 | 19 | 14  | 41 | 30.1 | 19 | 14   | 136| 100% |

β effect size = 0.3168
χ²ss = 4.6, P = 0.0319

†n = 7 of Nx diagnosis were not included. CI, confidence interval.

**Table 7** The answer to systemic chemotherapy according to genotype −725C > G > T

| −725C > G > T | Partial regression | Stabilization | Progression | Total |
|---------------|--------------------|---------------|-------------|-------|
| CC            | 8                  | 12            | 9           | 29    |
| CG            | 3                  | 3             | 3           | 9     |
| CT            | 1                  | 1             | 0           | 2     |
| GG            | 0                  | 1             | 0           | 1     |
| GT            | 0                  | 0             | 0           | 0     |
| Total         | 12                 | 17            | 12          | 41†   |

β effect size = 0.21; CI 95% (−0.69; 1.11)
χ²ss = 0.209, P = 0.6472

†n = 8 patients the results of chemotherapy were not known. CI, confidence interval.
therapy, then the homozygous TT patient has an OR 1.48 times higher chance of reacting with stabilization or progression. However, the 95% CI shows that we cannot exclude that there is no such dependence. The problem here concerns small groups of patients.

**Discussion**

Theoretically, each tissue may express HLA-G, and the nucleotide polymorphism of the gene may influence regulation mechanisms.\(^27,29\) Studies on the variability of the HLA-G gene’s promoter proved that the level of HLA-G gene transcription and HLA-G expression could be affected by SNPs.\(^33,34\) We focused on the \(-725C>G>T\) SNP, because it is located close to the interferon regulatory factor-1 binding sequence and has already been found to be associated with several diseases, such as multiple sclerosis,\(^32\) end-stage renal disease,\(^35\) and sporadic miscarriage.\(^36\) Its G allele creates a potential methylation site. As we know, the polymorphic sites \(-725C>G>T\) and \(-716T>G\) are near the interferon-specific regulatory element at the \(-744\) site, which binds interferon response factor 1.\(^29\) Polymorphisms may, thus, have an impact on the regulation of gene expression.\(^34,37\) The examined SNPs may affect the activity of the promoter by influencing the binding place, which may lead to HLA-G expression.\(^38\)

We also checked \(-716T>G\) simply because it was located on the same PCR product and influenced the migration in TGGE. The TGGE technique was chosen as the only method (apart from sequencing, which is more expensive) that differentiates between \(-725\) alleles C, G, and T (the T allele was omitted in other studies).

In 2001, Urosevic et al. described messenger ribonucleic acid of HLA-G in lung cancer cells and lymphocytes, macrophages, and dendritic cells infiltrating the tumor, which was correlated with advanced stages of the disease and poor prognosis.\(^39\) Subsequent studies showed HLA-G expression in NSCLC cells, which also correlated with lymph node metastases.\(^40,41\) HLA-G expression may then be an independent prognostic marker of the disease course.

Our study focused on polymorphism of the promoter of the HLA-G gene in patients diagnosed with lung cancer. Patients were diagnosed and treated according to the recommendations. The study revealed no relationship between described SNPs and lung cancer morbidity and mortality. The only statistically significant correlation concerned the extent of metastases to lymph nodes: we noted a more advanced N stage in patients with more C alleles at the \(-725\) site. This fact may confirm the role of HLA-G expression as prognostic marker. Other correlations did not reach the level of statistical significance and may need a larger sample size. According to our knowledge there have been no previous reports in the literature relating to the SNPs we examined: other HLA-G gene SNPs in lung cancer.

**Conclusion**

SNPs of the promoter of the HLA-G gene may have an impact on the development of lymph node metastases.

**Disclosure**

No authors report any conflict of interest.

**References**

1. GLOBOCAN. 2008 (JARC) Section of Cancer Information, [Cited 16 Aug 2012.] Available from URL: http://www.globocan.iarc.fr.
2. National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program [Cited 16 Aug 2012.] Available from URL: http://www.seer.cancer.gov.
3. Travis WD, Brambilla E, Müller-Hermelink HK, Harris CC, eds. Pathology & Genetics: Tumours of the Lung, Pleura, Thymus and Heart. IARC Press, Lyon 2004.
4. Travis WD, Brambilla E, Noguchi M et al. The new International Association for the Study of Lung Cancer/American Thoracic Society/European Multidisciplinary Respiratory Society International...
Multidisciplinary Classification of Lung Adenocarcinoma. J Thorac Oncol 2011; 6: 244–85.
5 Alberts WM. Diagnosis and management of lung cancer executive summary: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007; 132 (3 Suppl.): 15–195.
6 Scott WJ, Howington J, Feigenberg S, Movas B, Pisters K. Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007; 132 (3 Suppl.): 234S–42S.
7 Robinson LA, Ruckdeschel JC, Wagner H Jr, Stevens CW. Treatment of non-small cell lung cancer stage IIIa: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007; 132 (3 Suppl.): 243S–65S.
8 Jett JR, Schild SE, Keith RL, Kesler KA. Treatment of non-small cell lung cancer, stage IIIb: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007; 132 (3 Suppl.): 266S–76S.
9 Sociáski MA, Crowell R, Hensing TE et al. Treatment of non-small cell lung cancer stage IV: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007; 132 (3 Suppl.): 277S–89S.
10 Burnet FM. Cancer – a biological approach. Br Med J 1957; 1: 841–7.
11 Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: From immunosurveillance to tumor escape. Nat Immunol 2002; 3: 991–8.
12 Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Immunol 2006; 6: 836–48.
13 Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: Integrating immunity’s roles in cancer suppresion and promotion. Science 2011; 331: 1565–70.
14 Ferrone S, Marincola FM. Loss of HLA class I antigens by melanoma cells: Molecular mechanisms, functional significance and clinical relevance. Immunol Today 1995; 16: 487–94.
15 Algarra I, García-Lora A, Cabrera T, Ruiz-Cabello F, Garrido F. The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: Implications for tumor immune escape. Cancer Immunol Immunother 2004; 53: 904–10.
16 Seliger B, Harders C, Lohmann S et al. Down-regulation of the MHC class I antigen-processing machinery after oncogenic transformation of murine fibroblasts. Eur J Immunol 1998; 28: 122–33.
17 Schmidt-Wolf G, Schmidt-Wolf IG. Cytokines and gene therapy. Immunol Today 1995; 16: 173–5.
18 Strominger JL. Human histocompatibility proteins. Immunol Rev 2002; 185: 69–77.
19 Marsh SG, Albert ED, Bodmer WF et al. Nomenclature for factors of the HLA system, 2010. Tissue Antigens 2010; 75: 291–455.
20 Yan WH. Human leukocyte antigen-G in cancer: Are they clinically relevant? Cancer Lett 2011; 311: 123–30.
21 Favier B, LeMaoult J, Carosella ED. Functions of HLA-G in the immune system. Tissue Antigens 2007; 69 (Suppl 1): 150–2.
22 Carosella ED, Horuzsko A. HLA-G and cancer. Semin Cancer Biol 2007; 17: 411–2.
23 Urosevic M, Dummer R. HLA-G and IL-10 expression in human cancer – different stories with the same message. Semin Cancer Biol 2003; 13: 337–42.
24 Carosella ED, Favier B, Ronas-Freiss N, Moreau P, LeMaoult J. Beyond the increasing complexity of the immunomodulatory HLA-G molecule. Blood 2008; 111: 4862–70.
25 Shih IM. Application of human leukocyte antigen-G expression in the diagnosis of human cancer. Hum Immunol 2007; 68: 272–6.
26 Tan Z, Shon AM, Ober C. Evidence of balancing selection at the HLA-G promoter region. Hum Mol Genet 2005; 14: 3619–28.
27 Castelli EC, Mende-Junior CT, Veiga-Castelli LC, Roger M, Moreau P, Donadi EA. A comprehensive study of polymorphic sites along the HLA-gene: Implication for gene regulation and evolution. Mol Biol Evol 2011; 28: 3069–86.
28 Donadi EA, Castelli EC, Arnaiz-Villena A, Roger M, Rey D, Moreau P. Implications of the polymorphism of HLA-G on its function, regulation, evolution and disease association. Cell Mol Life Sci 2011; 68: 369–95.
29 Moreau P, Flajollet S, Carosella ED. Non-classical transcriptional regulation of HLA-G: An update. J Cell Mol Med 2009; 13 (9B): 2973–89.
30 Rami-Porta R, Crowley JJ, Goldstraw P. The revised TNM staging system for lung cancer. Ann Thorac Cardiovasc Surg 2009; 15: 4–9.
31 Oken MM, Creech RH, Torrey DC et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Ann J Clin Oncol 1982; 5: 649–55.
32 Wiśniewski A, Bilińska M, Klimczak A et al. Association of the HLA-G gene polymorphism with multiple sclerosis in a Polish population. Int J Immunogenet 2010; 37: 307–11.
33 Amiot L, Ferrone S, Grosse-Wilde H, Seliger B. Biology of HLA-G in cancer: A candidate molecule for therapeutic intervention? Cell Mol Life Sci 2011; 68: 417–31.
34 Ober C, Billstrand C, Kuldank S, Tan Z. The miscarriage-associated HLA-G-725 allele influences transcription rates in JEG-3 cells. Hum Reprod 2006; 21: 1743–8.
35 Misra MK, Prakash S, Kapoor R, Pandey SK, Sharma RK, Agrawal S. Association of HLA-G promoter and 14-bp insertion-deletion variants with acute allograft rejection and end-stage renal disease. Tissue Antigens 2013; 82: 317–326.
36 Ober C, Aldrich CL, Chervoneva I et al. Variation in the HLA-G promoter region influences miscarriage rates. Am J Hum Genet 2003; 72: 1425–35.
37 Mouillot G, Marcou C, Rousseau P, Ronas-Freiss N, Carosella ED, Moreau P. HLA-G gene activation in tumor cells involves cis-acting epigenetic changes. Int J Cancer 2005; 113: 928–36.
38 Moreau P, Moillot G, Rousseau P, Marcou C, Dausset J, Carosella ED. HLA-G gene repression is reversed by demethylation. Proc Natl Acad Sci USA 2003; 100: 1191–6.
39 Urosevic M, Kurrer MO, Kamarashev J et al. Human leucocyte antigen G up-regulation in lung cancer associates with high-grade histology, human leukocyte antigen class I loss and interleukin-10 production. *Am J Pathol* 2001; 159: 817–24.

40 Yie SM, Yang H, Ye SR, Li K, Dong DD, Lin XM. Expression of human leucocyte antigen G (HLA-G) is associated with prognosis in non-small cell lung cancer. *Lung Cancer* 2007; 58: 267–74.

41 Lin A, Zhu CC, Chen HX et al. Clinical relevance and functional implications for human leukocyte antigen-g expression in non-small-cell lung cancer. *J Cell Mol Med* 2010; 14: 2318–29.